Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma by Mouadh Benamar, Fadila Guessous, Kangping Du, Patrick Corbett, Joseph Obeid, Daniel Gioeli, Craig L. Slingluff Jr, Tarek Abbas

Get full text

Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma by Ileana S Mauldin, Nolan A Wages, Max O Meneveau, Kevin T Lynch, Samuel J Young, Craig L Slingluff Jr, Victor H Engelhard

Get full text

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63) by Kelly T Smith, Nikole Varhegyi, Nolan A Wages, Emily H Hall, Kathleen Haden, Craig L Slingluff, Jr., Lynn T Dengel, Anna Dickinson, Caroline Reed, Elizabeth M Gaughan, Varinder Kaur, Nadejda V Galeassi

Get full text

Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment by Ileana S Mauldin, Marit M Melssen, Stephen Turner, Pankaj Kumar, Karlyn E Pollack, Max O Meneveau, Kevin T Lynch, Alexander F Koeppel, Samuel J Young, Katia Sol-Church, Craig L Slingluff Jr

Get full text

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma by Mark E Smolkin, Gina R Petroni, Kimberly A Chianese-bullock, Kelly T Smith, Geoffrey Weiss, Nico Buettner, Mark Cobbold, Jeffrey Shabanowitz, Nikole Varhegyi, Elizabeth Gaughan, Victor H Engelhard, Rebecca C Obeng, Kara L Cummings, Angela L Ambakhutwala, Amanda Lulu, Paisley Myers, Keira E Mahoney, Emily H Hall, Kathleen Haden, Donald F Hunt, Craig L Slingluff, Jr

Get full text